Skip to main content
. 2015 Sep 29;18(5):667–678. doi: 10.1093/neuonc/nov243

Fig. 6.

Fig. 6.

Cediranib promotes cellular senescence in EGFRvIII-expressing GBM cells. (A) EGFRvIII-expressing U373MG cells were treated with cediranib (5 µM) (+) or vehicle (DMSO) (−) for 24 h and immunoblotted to detect phospho-VEGFR2 (P-VEGFR2 Y1059) and total VEGFR2. (B) EGFRvIII-expressing U373MG cells were treated with cediranib (5 µM) or vehicle for 24 h prior to adding BrdU (100 µM). BrdU-positive cells (red) were detected by immunofluorescence microscopy (representative fields are shown). (C) The percentage of BrdU-positive cells was determined for cediranib- or vehicle-treated cultures (mean ± SEM, n = 4, ***P < .01). (D) EGFRvIII-expressing U373MG cells were treated with cediranib (5 µM) or vehicle for 24 h. Immunoblot analysis was performed using the indicated antibodies. (E) EGFRvIII-expressing U373MG cells were treated with cediranib (5 µM) or vehicle. Senescence was determined by SA-β-Gal staining (blue). Representative fields are shown. (F) The percentage of SA-β-Gal-positive cells was determined, using ImageJ software, for cells treated with cediranib, cediranib + EGF (10 ng/mL), or vehicle (mean ± SEM, n = 4, **P < .01, ***P < .001, n.s., not statistically significant). (G) EGFRvIII-expressing U373MG cells were treated with cediranib (5 µM) or vehicle. Immunoblot analysis was performed using the indicated antibodies.